Search Videos and More

Showing 169 - 180 of 594 results

Previous| 1... 14 | 15 | 16 ...50 |Next


Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor News

Adolescent Glioma Subtype Responds to CDK4/6 Inhibitor

CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London.
Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation News

Dana-Farber President and CEO Laurie Glimcher, MD, Announces Her Plans to Step Down Capping a Highly Successful Tenure Marked with Discovery and Innovation

Acclaimed medical oncologist and researcher Benjamin Ebert, MD, PhD, appointed to lead the world-renowned cancer center
Dana-Farber Research News 9.01.2024 News

Dana-Farber Research News 9.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from August 1 through August 15.
Early Action, Better Outcomes: Transforming Cancer Prevention News

Early Action, Better Outcomes: Transforming Cancer Prevention

For more than 100 years, health advocates have spread the message that, with cancer, patience is not a virtue.
Dana-Farber Research Publication 8.15.2024 News

Dana-Farber Research Publication 8.15.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 16 through July 31.
FDA Approves New Therapy for Glioma Patients for First Time in Decades News

FDA Approves New Therapy for Glioma Patients for First Time in Decades

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. 
Dana-Farber Research Publication 8.01.2024 News

Dana-Farber Research Publication 8.01.2024

This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from July 1 through July 15.
Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention News

Rethinking Breast Cancer: Illuminating New Paths to Treatment and Prevention

Clinical trial data can often help scientists find answers in their quest to treat cancers. Sometimes, it can also reveal surprising new evidence about the drivers of disease, illuminating a new tactic for preventing cancer in the first place.
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy News

Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.
Bringing Advanced Medicines for Multiple Myeloma into Reach for All News

Bringing Advanced Medicines for Multiple Myeloma into Reach for All

Multiple myeloma is a cancer of the bone marrow. It affects plasma cells, which are mature forms of blood cells called B-lymphocytes.
In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer News

In a First, Immune Checkpoint Inhibitors Show Effectiveness in Metastatic Colorectal Cancer

In trial after clinical trial, metastatic colorectal cancer has been largely undeterred by immune checkpoint inhibitors. 
U.S. News & World Report names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2024-2025 News

U.S. News & World Report names Dana-Farber Brigham Cancer Center Among Nation’s Best for 2024-2025

For the 24th consecutive year, Dana-Farber Brigham Cancer Center has been recognized as a Best Hospital for cancer care by U.S. News & World Report.

Showing 169 - 180 of 594 results

Previous| 1... 14 | 15 | 16 ...50 |Next